Chronic fatigue syndrome differs from fibromyalgia. No evidence for elevated substance P levels in cerebrospinal fluid of patients with chronic fatigue syndrome. — CFSMEATLAS
Chronic fatigue syndrome differs from fibromyalgia. No evidence for elevated substance P levels in cerebrospinal fluid of patients with chronic fatigue syndrome.
Evengard, B, Nilsson, C G, Lindh, G et al. · Pain · 1998 · DOI
Quick Summary
Researchers measured a pain-signaling chemical called substance P in the spinal fluid of 15 people with ME/CFS. They found that all the ME/CFS patients had normal levels of this chemical. This is important because fibromyalgia—a condition with similar symptoms—typically shows elevated substance P levels. This finding suggests that ME/CFS and fibromyalgia may be caused by different biological problems, even though patients experience some overlapping symptoms.
Why It Matters
This study provides early evidence that ME/CFS has a different biological basis than fibromyalgia, which could eventually guide more targeted treatments for each condition. It validates that ME/CFS is a distinct disease entity rather than a variant of fibromyalgia, supporting the need for disease-specific research and clinical approaches.
Observed Findings
All 15 ME/CFS patients had cerebrospinal fluid substance P levels within normal range
Substance P levels differed significantly between ME/CFS and fibromyalgia patient groups
The majority of fibromyalgia patients in comparison literature showed elevated CSF substance P
This biochemical difference was observed despite clinical symptom overlap between the two conditions
Inferred Conclusions
ME/CFS and fibromyalgia are biologically distinct disorders with different underlying mechanisms
Elevated CSF substance P is a characteristic finding in fibromyalgia but not ME/CFS
The similar symptom presentations of these conditions may mask fundamentally different pathophysiological processes
Remaining Questions
What neurobiological mechanisms and biomarkers do characterize ME/CFS if not elevated substance P?
Are there other pain-signaling molecules or neuropathologic differences that distinguish these conditions?
Do ME/CFS and fibromyalgia patients with symptom overlap represent distinct pathogenic pathways or heterogeneous presentations of related conditions?
What This Study Does Not Prove
This study does not identify what actually causes ME/CFS or prove that substance P plays no role in ME/CFS pathophysiology overall—only that CSF levels are not consistently elevated as they are in fibromyalgia. It does not explain why the two conditions have overlapping symptoms or rule out other shared biological mechanisms. A single normal biomarker does not prove ME/CFS involves no neuropathic pain processes.